SynthesisInternational journal of nanomedicine2025
Advances in Nanotechnology in the Diagnosis and Treatment of Gynecological Cancers.
Synthesis in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mucus and tumor penetrating paclitaxel micelles for potent local therapy of cervical cancer.Journal of nanobiotechnology · 2026Article
- Breaking Physiological Barriers in Women's Health: Mucoadhesive and Stimuli-Responsive Nanomaterials.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology platforms facilitate therapeutic drug delivery and offer various advantages over conventional drugs, such as biocompatibility, non-inflammatory effects, high therapeutic output, biodegradability, non-toxicity, and biocompatibility. Due to the inherent drawbacks of conventional drug delivery to cancerous tissues, nanotechnology-based alternatives have been developed for such diseases. Gynecologic malignant tumors (GCs), include various types of cervical, endometrial, and ovarian cancers. The epidemiological characteristics of the tumors show that their incidence is increasing significantly and tends to be younger, which is a serious threat to women's physical and mental health. This article provides a systematic review of the latest research results on nanomaterials in the diagnosis and treatment of gynecological malignancies, including 2 sections on nanomaterials-based diagnostic and therapeutic strategies in gynecological cancers. In particular, the article also analyzes the challenges faced by nanotechnology, including toxicity, technology, and clinical translation issues. These applications not only improve the therapeutic efficacy of gynecological cancers, but also reduce the toxicity and side effects, and provide a new direction for the precise treatment of gynecological cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.